“Short Bowel Syndrome Pipeline Insight, 2022" report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Short Bowel Syndrome Market.
The Short Bowel Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Short Bowel Syndrome Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights about emerging therapies for the treatment of Short Bowel Syndrome and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Short Bowel Syndrome Treatment.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Short Bowel Syndrome market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Latest Clinical and Commercial Developments in the Short Bowel Syndrome Therapeutics Market
On September 30, 2022, Zealand Pharma A/S (CVR-no. 20045078,) announced positive results from the its pivotal Phase 3 trial of glepaglutide. Zealand Pharma’s glepaglutide is a long-acting GLP-2 analogue designed for once or twice-weekly subcutaneous delivery via an auto-injector in patients with short bowel syndrome (SBS).
On September 26, 2022, 9 Meters Biopharma, Inc. (NASDAQ:NMTR) announced positive final results from the Phase 2 study of vurolenatide and the outcome of its End-of-Phase 2 meeting with the US FDA. Vurolenatide is a proprietary long-acting GLP-1 receptor agonist in development for adults with short bowel syndrome (SBS).
As per DelveInsight, the Short Bowel Syndrome Therapeutics market is expected to increase in the coming years, owing to the increasing prevalence and the launch of emerging therapies.
Learn How the Ongoing Clinical & Commercial Activities will Affect the Short Bowel Syndrome Therapeutic Segment:
https://www.delveinsight.com/sample-request/short-bowel-syndrome-pipeline-insight
Short Bowel Syndrome Therapeutics Landscape
There are approx. 7+ key companies which are developing therapies for Short Bowel Syndrome. Currently, VectivBio AG has its Short Bowel Syndrome drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Short Bowel Syndrome Therapeutic Market include:
• VectivBio
• Zealand Pharma
• 9 Meters Biopharma
• Hanmi Pharmaceutical
• Adocia
• PhaseBio Pharmaceuticals
• Surrozen
• NPS Pharmaceuticals (Acquired by Shire Plc.)
And many others
Short Bowel Syndrome Drugs Covered in the report include:
• Apraglutide (VectivBio AG)
• Glepaglutide (Zealand Pharma)
• Gattex/teduglutide
And many more
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:
https://www.delveinsight.com/sample-request/short-bowel-syndrome-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Short Bowel Syndrome Current Treatment Patterns
4. Short Bowel Syndrome - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Short Bowel Syndrome Late Stage Products (Phase-III)
7. Short Bowel Syndrome Mid-Stage Products (Phase-II)
8. Short Bowel Syndrome Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Short Bowel Syndrome Discontinued Products
13. Short Bowel Syndrome Product Profiles
14. Key Companies in the Short Bowel Syndrome Market
15. Key Products in the Short Bowel Syndrome Therapeutics Segment
16. Dormant and Discontinued Products
17. Short Bowel Syndrome Unmet Needs
18. Short Bowel Syndrome Future Perspectives
19. Short Bowel Syndrome Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/short-bowel-syndrome-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“MELAS Syndrome Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the MELAS Syndrome Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
